Press Releases Cue Biopharma, Inc.

Equities

CUE

US22978P1066

Market Closed - Nasdaq Other stock markets 04:00:00 2024-06-07 pm EDT			5-day change	1st Jan Change
1.48 ^USD	-8.64%		-9.20%	-43.94%

Jun. 07	Cue Biopharma, Inc. Appoints Michael J. Fox to the Board of Directors and the Compensation Committee	CI
May. 09	Cue Biopharma, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI

Press Releases

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Cue Biopharma Presents Updated Data from Phase 1 Trial of CUE-101 in Recurrent/Metastatic HPV+ Head and Neck Cancer at the 2024 ASCO Annual Meeting	Jun. 04	GL
Cue Biopharma Presents Updated Data from Phase 1 Trial of CUE-101 in Recurrent/Metastatic HPV+ Head and Neck Cancer at the 2024 ASCO Annual Meeting	Jun. 04	AQ
Cue Biopharma to Present at Two Upcoming Investor Healthcare Conferences in June 2024	Jun. 03	GL
Cue Biopharma to Present at Two Upcoming Investor Healthcare Conferences in June 2024	Jun. 03	AQ
Cue Biopharma Reports First Quarter 2024 Financial Results and Recent Business Highlights	May. 09	GL
Cue Biopharma to Present at the 20th Annual PEGS Boston Summit	May. 08	GL
Cue Biopharma to Participate in Fireside Chat at The Citizens JMP Life Sciences Conference	May. 07	GL
Cue Biopharma to Present at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting	Apr. 24	GL
Cue Biopharma Reports Fourth Quarter and Full Year 2023 Financial Results and Updated Business Highlights	Apr. 08	GL
Cue Biopharma to Host Business Update Call and Webcast	Apr. 02	GL
Cue Biopharma’s Lead Clinical Asset, CUE-101, to be Featured at the 2024 Multi-disciplinary Head and Neck Cancers Symposium	Feb. 29	GL
Cue Biopharma to Present Corporate Update at the Oppenheimer 34th Annual Healthcare Life Sciences Conference	Feb. 06	GL
Cue Biopharma to Present Corporate Update at the Oppenheimer 34th Annual Healthcare Life Sciences Conference	Feb. 06	AQ
HPV+ Recurrent/Metastatic Head and Neck Cancer Pipeline, Clinical Trials Studies, Emerging Drugs, Mergers and Acquisition, Licensing, Agreements & Collaborations, and Latest News 2023 (Updated)	Nov. 23	AQ
Cue Biopharma to Present at the JMP Securities Hematology and Oncology Summit	Nov. 22	GL
Cue Biopharma Reports Third Quarter 2023 Financial Results and Recent Business Highlights	Nov. 09	GL
Cue Biopharma to Present at Three Upcoming Investor Healthcare Conferences in November	Nov. 07	GL
Cue Biopharma to Present at Three Upcoming Investor Healthcare Conferences in November	Nov. 07	AQ
Cue Biopharma Presents New Positive Data from Phase 1 Trials of CUE-101 in Head and Neck Cancer and CUE-102 in Wilms’ Tumor 1 Positive Cancers at SITC 2023	Nov. 03	GL
Cue Biopharma to Host Business Update Call and Webcast	Nov. 02	GL

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Press Releases Cue Biopharma, Inc.

Equities

CUE

US22978P1066

Press Releases

Filters